Pharsight

Drugs that contain Crizotinib

1. Xalkori patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8785632 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Mar, 2025

(8 months from now)

US7230098 PF PRISM CV Aminoheteroaryl compounds as protein kinase inhibitors
Aug, 2025

(1 year, 2 months from now)

US7858643 PF PRISM CV Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Oct, 2029

(5 years from now)

US8217057 PF PRISM CV Polymorphs of a c-MET/HGFR inhibitor
Nov, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7825137 PF PRISM CV Method of treating abnormal cell growth
May, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-852) Jan 14, 2024
New Indication(I-897) Jul 14, 2025

Market Authorisation Date: 07 September, 2023

Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage

XALKORI family patents

Family Patents